Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice

Iris L. Romero, Ilyssa O. Gordon, Sujatha Jagadeeswaran, Keeley L. Mui, Woo Seok Lee, Daniela M. Dinulescu, Thomas N. Krausz, Helen Kim, Melissa L. Gilliam, Ernst Lengyel*

*Corresponding author for this work

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Although epidemiologic evidence for the ability of combined oral contraception (OC) to reduce the riskof ovarian cancer (OvCa) is convincing, the biological mechanisms underlying this effect are largely unknown. We conducted the present study to determine if OC also influences ovarian carcinogenesis in a genetic mouse model and, if so, to investigate the mechanism underlying the protective effect. LSL-K-rasG12D/+PtenloxP/loxP mice were treated with ethinyl estradiol plus norethindrone, contraceptive hormones commonly used in combined OC, or norethindrone alone, or a gonadotropin- releasing hormone agonist. The combined OC had a 29% reduction in mean total tumor weight compared with placebo (epithelial tumor weight, -80%). Norethindrone alone reduced mean total tumor weight by 42% (epithelial tumor weight, -46%), and the gonadotropin-releasing hormone agonist increased mean total tumor weight by 71% (epithelial tumor weight, +150%). Large variations in tumor size affected the P values for these changes, which were not statistically significant. Nonetheless, the OC reductions are consistent with the epidemiologic data indicating a protective effect of OC. Matrix metalloproteinase-2 activity was decreased in association with OC, indicating that OC may affect ovarian carcinogenesis by decreasing proteolytic activity, an important early event in the pathogenesis of OvCa. In contrast, OC increased invasion in a K-ras/Pten OvCa cell line established from the mouse tumors, suggesting that OC hormones, particularly estrogen, may have a detrimental effect after the disease process is under way. Our study results support further investigation of OC effects and mechanisms for OvCa prevention.

Original languageEnglish (US)
Pages (from-to)792-799
Number of pages8
JournalCancer Prevention Research
Volume2
Issue number9
DOIs
StatePublished - Sep 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice'. Together they form a unique fingerprint.

  • Cite this

    Romero, I. L., Gordon, I. O., Jagadeeswaran, S., Mui, K. L., Lee, W. S., Dinulescu, D. M., Krausz, T. N., Kim, H., Gilliam, M. L., & Lengyel, E. (2009). Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prevention Research, 2(9), 792-799. https://doi.org/10.1158/1940-6207.CAPR-08-0236